Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

Male healthcare provider standing with his arms crossed, smiling

Here's Why Quest Diagnostics Made Investors Happy With Its Q3 Results

The company's business appears to be recovering nicely from the COVID-19 pandemic.

Girl holding clear aligner

Why Align Technology Stock Is Skyrocketing Today

The orthodontic-device maker delivered Q3 results that crushed expectations.

Marker on Nov. 3 with flag

3 Robinhood Stocks That Could Skyrocket If Joe Biden Wins in November

"Joe-mentum" could be on the way.

Man looking at coronavirus and chart images

2 Stocks to Buy as the Third Coronavirus Wave Hits

The COVID-19 pandemic will likely get worse before it gets better. These two stocks could be safe havens for investors.

$1 bill folded into an arrow pointing down

Why Aptinyx Stock Sank Today

Investors reacted negatively to the company's announcement of a secondary stock offering.

female lab worker using micro pipette in lab

Here's What to Really Like About Abbott Labs' Q3 Results

Revenue and earnings beats were only part of the story.

Healthcare professionals looking at PC

Why Phreesia Stock Is Flying Higher Today

Investors are confident about the company's prospects after its strong secondary stock offering pricing.

Gloved hands holding 2 COVID vaccine bottles

2 Late-Stage Coronavirus Vaccine Candidates in Limbo

U.S. phase 3 studies for AstraZeneca's and Johnson & Johnson's coronavirus vaccines still haven't resumed. Should investors be worried?

2 scientists in lab standing side by side

Better Buy: Moderna vs. Gilead Sciences

One of these biotechs appears to have stronger growth prospects over the near term.

White bag with cannabis leaf on it

Why Marijuana Stocks Aurora Cannabis, Canopy Growth, and Tilray Are Giving Up Much of Monday's Gains

It's nothing but the volatility that's typical for Canadian pot stocks.

Syringe and needle on top of calendar

3 Critical Near-Term Milestones to Watch With Pfizer's Coronavirus Vaccine

The first one could be just a few days away.

Magnifying glass over coronavirus and DNA

The 1 Stock Most Likely to Win From a Potentially Game-Changing Coronavirus Discovery

How COVID-19 is treated in the future could be altered by recent breakthrough research.

3 blocks with stars on them

These 3 Under-the-Radar Stocks Are Great Buys Right Now

You won't see many headlines about these stocks. But they're well positioned to deliver big gains.

2 jigsaw puzzle pieces

Why Endo International and BioSpecifics Technologies Stocks Soared Today

Investors are fired up about Endo's planned acquisition of BioSpecifics.

COVID-19 saliva test

Why OraSure Technologies Stock Is Soaring Today

The FDA granted Emergency Use Authorization for the company's at-home saliva collection device for coronavirus testing.

Two scientists working in a lab

Better Buy: Amgen vs. Bristol Myers Squibb

Here's how these two big drugmakers stack up against each other in several key categories.

Gloved hands holding vaccine bottle and syringe

Better Coronavirus Stock: Inovio Pharmaceuticals or VBI Vaccines?

Neither biotech is in the front of the pack in developing a COVID-19 vaccine.

Timeline with green pushpin on 2025

Where Will Novavax Be in 5 Years?

This small biotech might be a lot bigger by 2025.

Woman holding tablet with 3 stacks of coins

3 Dividend Stocks I'd Buy Right Now

Solid dividends plus strong growth prospects add up to great stocks to buy.

Woman extending arms with wooden line trending up

3 Stocks Poised to Be Surefire Winners in the New Bull Market

Each of them benefits from unstoppable trends.